Does everyone on a statin get diabetes?

No, nowhere close. The excess risk is about one extra case per 255 people over 4 years, so the large majority never develop diabetes because of a statin. And the risk is concentrated: people who are metabolically healthy, without prediabetes or extra weight, see almost none of it. The statin diabetes risk is a genuine but narrow effect rather than a fate that awaits everyone who takes one.

Does everyone on a statin get diabetes?

No, nowhere close. The excess risk is about one extra case per 255 people over 4 years, so the large majority never develop diabetes because of a statin. And the risk is concentrated: people who are metabolically healthy, without prediabetes or extra weight, see almost none of it. The statin diabetes risk is a genuine but narrow effect rather than a fate that awaits everyone who takes one.

Do Statins Cause Diabetes? What the Evidence Shows | Philadelphia

TL;DR30-second take

Yes, statins slightly raise the risk of developing type 2 diabetes, but the effect is small and the heart benefit clearly outweighs it. Across large trials, statins caused about one extra case of diabetes for every 255 people treated for 4 years, a roughly 9% relative increase. The risk falls mainly on people who are already close to diabetes, from prediabetes, extra weight, or metabolic syndrome; those at low metabolic risk see little or none. The diabetes tends to be mild, often in people heading there anyway. In the groups that do get it, statins still prevent many more heart attacks and strokes than the diabetes cases they cause, so the guidance is clear: do not avoid or stop a statin you need over this.

TL;DR: Yes, statins slightly raise the risk of developing type 2 diabetes, but the effect is small, concentrated in people who are already close to diabetes, and clearly outweighed by the protection statins give the heart. In large trials, statins caused roughly one extra case of diabetes for every 255 people treated for 4 years, about a 9% relative increase, a bit higher with intensive doses. The excess falls mainly on people who already have diabetes risk factors, like prediabetes, extra weight, or metabolic syndrome; those at low metabolic risk see little or none. The diabetes tends to be mild, often in people who were heading there anyway. And in the very groups that develop it, statins still prevent many more heart attacks and strokes than the diabetes cases they cause. The bottom line for most people: do not avoid or stop a statin you need over diabetes fear.

The short answer

Statins do slightly increase the risk of new type 2 diabetes. This is a genuine effect rather than a myth or a measurement quirk: it has shown up in randomized trials, it gets a little larger with higher statin doses, and it is even supported by genetics. So it deserves a clear answer rather than dismissal.

But that answer has three parts that change everything: the risk is small, it falls mainly on people already near diabetes, and it is dwarfed by the heart benefit. Miss any of those, and the number becomes a scare rather than a fact.

How big is the risk?

The landmark evidence is a 2010 analysis that pooled 13 statin trials with more than 90,000 people.¹ It found that statins raised the risk of new diabetes by about 9%. That sounds notable until you translate it into absolute terms: treating 255 people with a statin for 4 years produced one extra case of diabetes. Put another way, over those 4 years, 254 of every 255 people saw no diabetes they would not have gotten anyway.

Higher doses carry a slightly larger risk. A 2011 analysis comparing intensive-dose to moderate-dose statins found about a 12% higher rate of new diabetes on the intensive regimens, which works out to roughly 2 extra cases per 1,000 people per year.² The same intensive doses also prevented more heart attacks and strokes, so the trade was still favorable, but it is a reason a physician might choose a moderate dose for someone at high diabetes risk who does not need the maximum.

Who develops the diabetes?

This is the part most often left out, and it changes the whole picture. The extra diabetes does not fall evenly; it falls mainly on people who were already close to it.

In the JUPITER trial, when researchers split participants by whether they had any diabetes risk factors, like prediabetes, obesity, high blood sugar, or metabolic syndrome, the entire diabetes signal was in the group that had at least one. Among participants with no diabetes risk factors, there was no detectable increase in diabetes at all, only the heart benefit. Statins, in other words, do not create diabetes out of nowhere; they nudge people who are already at the edge over the line a little sooner. For a metabolically healthy person, the diabetes risk from a statin is close to zero.

Does the benefit outweigh the risk?

Clearly, and this is the number that should anchor the whole decision. The same JUPITER trial did the accounting directly. Even among the higher-risk participants, the ones who developed the extra diabetes, statins prevented 134 heart attacks, strokes, and deaths for every 54 new cases of diabetes.³ More than twice as many serious cardiovascular events avoided as diabetes cases caused, in the very group most prone to the diabetes.

That ratio captures the heart of the matter. Diabetes is a manageable condition, above all when caught at the mild, early stage these statins tend to produce; a heart attack or stroke is often neither manageable nor reversible. Trading a modest, monitorable rise in diabetes risk for a substantial drop in heart attacks and strokes is a good trade for anyone who has a clear reason to be on a statin.

What kind of diabetes, and why does it happen?

The diabetes statins bring on tends to be mild. On average, statins nudge blood sugar up only slightly, by a few points, and most of the extra cases are people who were already in the prediabetes range and cross the diagnostic line a bit earlier than they otherwise would have. This does not make the diabetes fake, and it still deserves proper management, but it does mean statins are rarely turning healthy people into severe diabetics; they are mostly accelerating a diagnosis that was already coming.

Why it happens is not fully understood. The leading ideas are that statins slightly reduce the body's sensitivity to insulin, or slightly blunt the pancreas's insulin output, or both. The effect appears to be a genuine consequence of how the drugs work rather than a coincidence: people who carry gene variants that mimic a statin's action, lowering cholesterol through the same target, also show a small increase in weight and diabetes risk.⁴ That genetic fingerprint is part of why the diabetes effect is taken seriously rather than dismissed.

What should you do about it?

The guidance is settled, and it is reassuring. If you have a clear reason to take a statin, such as existing heart disease, a high ApoB, or high overall cardiovascular risk, the diabetes risk is not a reason to avoid or stop it. The heart benefit outweighs it, often by a wide margin.

What does make sense, if you are at higher diabetes risk, is to fold that into the plan rather than to skip the statin. That means checking blood sugar or HbA1c before starting and periodically after, choosing a moderate dose when a maximum is not needed, and emphasizing the lifestyle steps that lower diabetes risk on their own: losing excess weight, staying active, and cutting the refined carbohydrate and sugar that push blood sugar up. Those steps can offset much of the statin's effect, and they protect the heart too. The goal is to get the cholesterol benefit while keeping an eye on the blood sugar, rather than forcing a choice between the two.

Guidance from the Clinic

"This is one of the most common worries I hear, and I understand it, because the headline 'statins cause diabetes' sounds alarming. What I do is put it in proportion. Yes, statins can nudge someone who is already near diabetes over the line, a little sooner than otherwise. But the number is small, it barely touches metabolically healthy people, and in the patients who do get it, the statin is preventing more than twice as many heart attacks and strokes as the diabetes cases it causes. I would never let a fear of mild, manageable diabetes talk a high-risk patient out of a drug that could prevent a heart attack. What I do instead is watch the blood sugar and double down on the lifestyle that protects against both. You do not have to choose between your heart and your blood sugar; you protect both, with the statin as one part of the plan."

Key Takeaways

Statins slightly increase the risk of new type 2 diabetes, by about 9% in relative terms, or roughly one extra case per 255 people treated for 4 years; intensive doses carry a bit more.
The excess risk falls mainly on people already close to diabetes, from prediabetes, extra weight, or metabolic syndrome; metabolically healthy people see little or none.
The heart benefit clearly outweighs the diabetes risk: even in the higher-risk group that develops it, statins prevent more than twice as many heart attacks, strokes, and deaths as the diabetes cases they cause.
The diabetes tends to be mild and early, often in people heading there anyway, and it is manageable; it is a genuine effect but a narrow and small one.
If you have a clear reason to take a statin, do not avoid or stop it over diabetes risk; instead monitor blood sugar, consider a moderate dose, and emphasize lifestyle, which lowers both risks at once.

Nervous About Statins? - working through the common statin worries
Beyond Statins: Lowering Cholesterol - the other cholesterol drugs, including diabetes-neutral options
ApoB and Heart Health - the particle count that decides who needs a statin
Metabolic Health and Insulin Resistance - lowering diabetes risk on its own
What Is a Preventive Cardiologist? - how these individual decisions get made

Scientific References

Sattar N, Preiss D, Murray HM, et al. "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials." Lancet. 2010;375(9716):735-742.
Preiss D, Seshasai SR, Welsh P, et al. "Risk of Incident Diabetes with Intensive-Dose Compared with Moderate-Dose Statin Therapy: a Meta-analysis." JAMA. 2011;305(24):2556-2564.
Ridker PM, Pradhan A, MacFadyen JG, et al. "Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: an Analysis from the JUPITER Trial." Lancet. 2012;380(9841):565-571.
Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. "HMG-Coenzyme A Reductase Inhibition, Type 2 Diabetes, and Bodyweight: Evidence from Genetic Analysis and Randomised Trials." Lancet. 2015;385(9965):351-361.

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Because the heart benefit is much larger than the diabetes risk. In the trials, even among the higher-risk people who developed the extra diabetes, statins prevented more than twice as many heart attacks, strokes, and deaths as the diabetes cases they caused. Diabetes at the mild stage statins produce is manageable; a heart attack often is not. For someone with a clear reason to take a statin, the trade strongly favors taking it.

No, and never on your own. If you have a reason to be on a statin, stopping it to avoid a small, manageable diabetes risk trades a large heart benefit for a small one, which is the wrong direction. If you are worried about blood sugar, the better move is to talk with your doctor about monitoring it, possibly using a moderate dose, and strengthening the lifestyle habits that lower diabetes risk. Do not stop a statin over this without that conversation.

The risk is a class effect, so all statins carry some, but it tends to track with intensity: higher, more potent doses carry a bit more diabetes risk than lower ones. For a person at high diabetes risk who does not need maximum cholesterol lowering, a moderate dose of a statin, or pairing a lower statin dose with another cholesterol drug like ezetimibe, can hold the diabetes risk down while still protecting the heart. The specific choice is one to make with your physician.

Deep-Dive Questions

Because a risk has two dimensions: how much it raises your chances, and how high your chances were to begin with. Statins raise diabetes risk by a small relative amount, about 9%, and that percentage acts on your underlying risk. For someone with prediabetes and extra weight, whose baseline diabetes risk is already high, a 9% bump can be the nudge that crosses the line. For someone lean and metabolically healthy, whose baseline risk is low, the same 9% of a small number is close to nothing. The relative risk is the same; the absolute effect depends on where you started, which is why the diabetes shows up in the predisposed and barely registers in everyone else.

It appears to be ordinary type 2 diabetes, generally caught early and mild. Most of the excess cases are people who were already prediabetic and cross the diagnostic threshold somewhat sooner than they would have on their own. There is no evidence that statin-associated diabetes is a distinct or more dangerous form; it is the same condition, often diagnosed at a milder point. That matters for two reasons: it is manageable with the usual tools, and much of it represents earlier detection of something already underway rather than a wholly new disease.

The candid answer is that the connection is not fully mapped, but it is a genuine one. Statins block an enzyme called HMG-CoA reductase to lower cholesterol, and that same target seems to have modest effects on how the body handles glucose, possibly by slightly reducing insulin sensitivity or the pancreas's insulin release. The strongest clue that this is a true consequence of the mechanism, rather than an accident, comes from genetics: people born with gene variants that lower cholesterol through the same pathway also tend to weigh slightly more and have a slightly higher diabetes risk. So the blood-sugar effect appears to be woven into cholesterol-lowering through this target, at a small scale.

Largely no, and that is informative. The diabetes signal is specific to statins and their target; the other main cholesterol drugs do not carry the same clear effect. Ezetimibe, which blocks cholesterol absorption, and the PCSK9 inhibitors, which clear LDL through a different mechanism, have not shown the statin-like diabetes risk. This supports the idea that the effect is tied to how statins in particular work, rather than to cholesterol lowering in general. For a person at high diabetes risk who needs more cholesterol lowering, that can be a reason to add one of these drugs rather than push the statin dose to its maximum.

Ready when you are